Out of 400 Irish wolfhounds cardiologically examined, echocardiographic measurements of 262 normal dogs were analyzed to obtain reference values for the breed. Based on regression analysis, several echocardiographic parameters showed significant linear correlation with body weight and with age, but coefficients of determination were low. Therefore, due to a high individual variability of echocardiographic measurements in adult Irish wolfhounds, the predictive value of body weight for echocardiographic measurements was clinically not relevant. Sex had no influence on echocardiographic values. For the estimation of myocardial function, end-systolic volume index (ESVI) (mean, 29.0 ml/m2 +/- standard deviation [SD], 5.9 ml/m2) was determined for the group of 262 normal dogs.

BackgroundDilated cardiomyopathy (DCM) is a common cause of morbidity and mortality in the Irish Wolfhound (IW). However, the benefit of medical treatment in IW dogs with preclinical DCM, atrial fibrillation (AF), or both has not been demonstrated.ObjectivesCompare the time to develop congestive heart failure (CHF) or sudden death in IW dogs with preclinical DCM, AF, or both receiving monotherapy with pimobendan, methyldigoxin, or benazepril hydrochloride.AnimalsSeventy‐five client‐owned IW dogs.MethodsIrish Wolfhound dogs were prospectively randomized to receive pimobendan (Vetmedin®)1, benazepril HCl (Fortekor®)2, or methyldigoxin (Lanitop®)3 monotherapy in a 1:1:1 ratio in a blinded clinical trial. The prospectively defined composite primary endpoint was onset of CHF or sudden death. To assure stringent evaluation of treatment effect, data from dogs complying with the study protocol were analyzed.ResultsSixty‐six IW fulfilling the study protocol included 39 males, 27 females; median (interquartile range) age, 4.0 years (3.0–5.0 years) and weight, 70.0 kg (63.0–75.0 kg). Primary endpoint was reached in 5 of 23 (21.7%) IW receiving pimobendan, 11 of 22 (50.0%) receiving benazepril HCl, and 9 of 21 (42.9%) receiving methyldigoxin. Median time to primary endpoint was significantly longer for pimobendan (1,991 days; 65.4 months) compared to methyldigoxin (1,263 days; 41.5 months; P = .031) or benazepril HCl‐(997 days; 32.8 months; P = .008) treated dogs.Conclusions and Clinical ImportanceIn IW dogs with preclinical DCM, AF or both, pimobendan monotherapy significantly prolonged time to onset of CHF or sudden death than did monotherapy with benazepril HCl or methyldigoxin.

No abstract